| http://www.w3.org/ns/prov#value | - All statements, other than historical facts included in this press release, including statements regarding: the Company???s plan to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of additional doses of INX-189 and INX-005, administered as monotherapy or in combination with ribavirin for seven days in its ongoing Phase 1b extension trial; the Company???s plan to submit a
|
